Life Sciences

Dynavax axes immuno-oncology pipeline and 82 staff

May 27, 2019

Dynavax is pulling out of immuno-oncology R&D, laying off 82 staff and parting company with its CEO. The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B. California-based Dynavax tied its fate to TLR9 agonist SD-101 and other cancer assets..

That was fast: Ex-FDA commissioner goes back to biotech investing

May 24, 2019

Less than two months after stepping down as FDA commissioner, Scott Gottlieb has slipped right back into his old ways, becoming “special partner” at his former life science venture capital firm New Enterprise Associates (NEA). Gottlieb, who has taken a while to shake off the..

Medical affairs: Key imperatives for engaging and educating physicians in a digital world

May 23, 2019

As the trend toward medical affairs (MA) becomes an even more significant part of biopharmaceutical companies, MA teams have emerged as key players not only in advancing the success of their companies, but also in helping to improve patient outcomes. Underpinning this role is their..

Chugai ponies up $1B+ to combine R&D operations in Yokohama

May 22, 2019

Chugai Pharmaceuticals is shelling out ¥127.3 billion ($1.15 billion) on a new R&D site in Yokohama, where it will combine the work of two long-standing research labs in nearby cities. It will start building the new facility this August. The two labs, located in Gotemba..

Amgen to buy Copenhagen-based Nuevolution for $167 million

May 22, 2019

Amgen, the world’s largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery. Copenhagen-headquartered Nuevolution said its board unanimously recommended Amgen’s cash offer of 32.5 Swedish crowns per..

Industry experts weigh in on slew of bills aimed at drug price transparency at hearing

May 22, 2019

Experts from across the healthcare system weighed in on several House bills aimed at increasing transparency in the pharmaceutical supply chain at a hearing Tuesday. Seven pieces of legislation, all of which are bipartisan, were on the slate for discussion at the House Energy and..

WuXi to build dedicated vaccine facility, but who’s the client?

May 21, 2019

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a contract that should produce $150 million a year for 20 years. It just didn’t identify the client. The Chinese CDMO Monday announced the letter of..

Merck boosts late-phase cancer pipeline with $1.1B Peloton buy

May 21, 2019

Merck has struck a deal to buy Peloton Therapeutics for $1.1 billion upfront days before the biotech was due to list on Nasdaq. The deal will give Merck control of an experimental oral HIF-2α inhibitor that could challenge Keytruda for the metastatic renal cell carcinoma..

Industry steps up interest in developing world

May 20, 2019

The pipeline of drugs and vaccines aimed at diseases prevalent in low- and middle-income countries has more than doubled since 2014, according to the Access to Medicine Foundation (AMF). However, the trend was driven by surging activity in noncommunicable diseases, leaving many conditions underserved by..

Refueling the innovation engine in vaccines

May 20, 2019

From a global public-health standpoint, vaccines are considered some of the most important inventions in human history. Some notable achievements of vaccines include the eradication of smallpox and the near eradication of poliovirus. Approximately 300 million people died of smallpox between 1900 and 1980, and..

CLIENT PORTAL